Un audited financial Results for the quarter and half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals announced its Q2 and H1 FY26 results on November 13, 2025. Total revenue for Q2 FY26 came in at Rs 165.49 lakhs, down from Rs 250.17 lakhs in the same quarter last year, a drop of roughly 34% year-on-year. Loss before tax widened sharply to Rs 362.21 lakhs in Q2, compared with a Rs 125.20 lakh loss in Q2 FY25, and net loss for the quarter was Rs 258.85 lakhs. The company recognised a Rs 205.43 lakh provision for Expected Credit Loss on long-pending trade receivables under Ind AS 109. It also issued 10.25 million convertible share warrants, receiving Rs 307.50 lakhs as 25% upfront subscription. Net cash from operating activities remained negative at around Rs 367.89 lakhs for H1 FY26.
A sharp revenue fall, widening quarterly losses, and a sizeable credit-loss provision on aged receivables point to continued financial stress. Persistent cash burn and weak operating performance are likely to weigh negatively on investor sentiment and the stock price.